Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives
G Sartori, L Belluomini, F Lombardo… - Expert Review of …, 2020 - Taylor & Francis
… (LUX-lung 2), patients who received afatinib 40 … afatinib discontinuation were interstitial
lung disease, rash/acne, vomiting and paronychia. Overall, 67% of patients who received afatinib …
lung disease, rash/acne, vomiting and paronychia. Overall, 67% of patients who received afatinib …
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
JCH Yang, MJ Ahn, NJ Dickgreber, B Halmos, V Hirsh… - 2015 - ascopubs.org
… We performed post-hoc analyses on the influence of afatinib … LUX-Lung 3 (LL3) trial, and
analyzed dose reduction data collected in clinical practice. Methods: All pts treated with afatinib …
analyzed dose reduction data collected in clinical practice. Methods: All pts treated with afatinib …
[HTML][HTML] Afatinib, an irreversible ErbB family blocker for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer
Y Summers, DM Graham - European Journal of Oncology …, 2019 - journals.lww.com
… The LUX-Lung 3 and 6 phase III studies showed greater … line afatinib compared with
platinum-doublet chemotherapy, whereas LUX-Lung 7 highlighted the enhanced benefits of afatinib …
platinum-doublet chemotherapy, whereas LUX-Lung 7 highlighted the enhanced benefits of afatinib …
Survival outcomes of nonsmall cell lung cancer patients treated with Afatinib who are affected by early adverse events
… LUX-Lung 3 and LUX-Lung 6 were randomized trials of afatinib versus pemetrexed-cisplatin …
the per-protocol patients from the afatinib arms of LUX-Lung 3 and LUX-Lung 6. Secondary …
the per-protocol patients from the afatinib arms of LUX-Lung 3 and LUX-Lung 6. Secondary …
[HTML][HTML] Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
S Watanabe, H Hayashi… - Annals of Translational …, 2016 - ncbi.nlm.nih.gov
… Afatinib has been even … for LUX-Lung 2, a phase II study of afatinib for patients with EGFR
mutation-positive NSCLC, found that the overall RR did not differ significantly between patients …
mutation-positive NSCLC, found that the overall RR did not differ significantly between patients …
[HTML][HTML] … Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and …
… , thus, LUX-Lung (LL) trials investigating afatinib allowed enrolment of patients (pts) with
brain metastases (BM). LL3, 6 and 7 previously demonstrated activity of afatinib in pts with BM, …
brain metastases (BM). LL3, 6 and 7 previously demonstrated activity of afatinib in pts with BM, …
[HTML][HTML] Patient-Reported Outcomes (Pros) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) Receiving Afatinib (A) Monotherapy Followed By a+ …
…, V Chand, M Schuler, LUX-Lung 5 Investigators - Annals of …, 2014 - Elsevier
Aim: A is an irreversible ErbB family blocker. In Part A of the open-label LL5 study, pts with
advanced NSCLC who had failed ≥1 line of chemotherapy and erlotinib/gefitinib received A (…
advanced NSCLC who had failed ≥1 line of chemotherapy and erlotinib/gefitinib received A (…
[HTML][HTML] … second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung …
…, J Love, V Chand, JC Soria, LUX-Lung 8 Investigators - Annals of …, 2014 - Elsevier
Aim: A is an irreversible ErbB family blocker that has shown promising clinical activity in pts
with SCC of the head/neck and lung. Here, we report results of LL8, a phase III trial that …
with SCC of the head/neck and lung. Here, we report results of LL8, a phase III trial that …
[HTML][HTML] OA23. 05 First-line afatinib versus gefitinib in EGFRm+ advanced NSCLC: updated overall survival analysis of LUX-Lung 7
K Park, EH Tan, L Zhang, V Hirsh, K O'Byrne… - Journal of Thoracic …, 2017 - jto.org
… 25% (afatinib) and 13% (gefitinib) of patients received treatment for >24 months. 73%
and 77% of patients in the afatinib and gefitinib arms had ≥1 subsequent systemic anti-cancer …
and 77% of patients in the afatinib and gefitinib arms had ≥1 subsequent systemic anti-cancer …
[HTML][HTML] Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world …
B Halmos, EH Tan, RA Soo, J Cadranel, MK Lee… - Lung Cancer, 2019 - Elsevier
… Baseline characteristics of these 155 patients were … for afatinib-treated patients in the
LUX-Lung 3 trial (Table 1); however, in RealGiDo patients were older, there were more patients …
LUX-Lung 3 trial (Table 1); however, in RealGiDo patients were older, there were more patients …